Inhaled budesonide for early treatment of COVID-19. | Lancet Respir Med;9(7): e59, 2021 07. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Inhaled budesonide for early treatment of COVID-19.

Zeitlinger, Markus; Idzko, Marco.

Zeitlinger M; Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria. Electronic address: markus.zeitlinger@meduniwien.ac.at.
Idzko M; Department of Internal Medicine II, Division of Pulmonology, Medical University of Vienna, 1090 Vienna, Austria.

Lancet Respir Med ; 9(7): e59, 2021 07.

Article in English | MEDLINE | ID: covidwho-1337047

Subject(s)

Budesonide; COVID-19; Administration, Inhalation; Bronchodilator Agents/therapeutic use; Humans; SARS-CoV-2

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Budesonide / COVID-19 Limits: Humans Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Budesonide / COVID-19 Limits: Humans Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article